A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1007/s00280-016-3010-1
Published Online: 2016-03-30
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shimizu, Toshio
Fukuoka, Kazuya
Takeda, Masayuki
Iwasa, Tutomu
Yoshida, Takeshi
Horobin, Joanna
Keegan, Mitchell
Vaickus, Lou
Chavan, Ajit
Padval, Mahesh
Nakagawa, Kazuhiko
Funding for this research was provided by:
Verastem, Inc.
License valid from 2016-03-30